Despite the recent entry into the market-place of a range of new pharmacological treatments for epilepsy, most patients still receive the standard antiepileptic drugs. This review considers the clinical place and practical use of these agents. Detailed consideration is given to carbamazepine, phenytoin, sodium valproate, phenobarbital and ethosuximide, with lesser emphasis on primidone, clobazam and clonazepam. Individualization of therapy, polypharmacy, refractory epilepsy, therapeutic drug monitoring, pregnancy, withdrawing treatment, epilepsy prophylaxis and referral to an epilepsy centre are also discussed. The paper concludes with a statement of 12 basic rules in prescribing established antiepileptic drugs.
INTRODUCTION
Around 50 million people have epilepsy. The annual incidence varies between 20 and 70 individuals per 100,000' with a point prevalence of o.4-o.8%2. Incidence rates are highest in childhood, plateau from 15 to 65 years, and rise again in the elderly. Overall, 5% of the world's population will have a seizure at some time in their lives. These figures exclude febrile convulsions, which manifest in approximately 5% of children. They do, however, support a substantial remission rate that can occur in patients who have never received treatment with an antiepileptic drug3. There is evidence, too, that the more seizures a patient experiences before treatment is begun, the more likely the epilepsy is to prove refractory4. This is likely to be a consequence of the severity of the underlying process5.
Seizures represent the clinical manifestation of a number of diverse neurological and systemic disorders in addition to a range of idiopathic (or genetic) epilepsies. A specific cause can currently be identified in only approximately 30% of patients6. The diagnosis is made from the description of the episodes and the clinical context in which they occur, supplemented on occasion by electronecephalography.
Antiepileptic drug therapy is usually begun when the patient has suffered more than one unprovoked seizure within a year. Although the majority of treated patients will remain fully controlled, as many a 30% will continue to suffer seizures in the face of optimal deployment of antiepileptic medication'. Despite the entry into the market-place of a range of new pharmacological treatments for epilepsy, most patients still receive the standard antiepileptic drugs. This review considers the current place and practical use of these agents.
WHEN TO TREAT
Most patients with recurrent epileptic seizures will require treatment. Seizures can cause injury secondary to falls, excessive muscular contractions associated with convulsive activity, and inappropriate automatisms. Their presence will prevent an individual from driving, and may interfere with a variety of important educational, vocational and social activities. In addition, although still somewhat controversial, there is growing concern that some types of seizures may cause brain injury, producing cognitive and memory problems, and promoting a propensity to further seizures. Finally, there is a low but significant mortality associated with uncontrolled seizures that has been estimated at approximately O.l-0.3% per year'. Patients may die during a seizure or may be found dead unexpectedly in the absence of direct evidence of a seizureg.
More controversial is the issue whether to treat a single seizure. This may be a consequence of severe sleep deprivation, vasovagal syncope, or drug or alcohol withdrawal. Patients suffering such a provoked seizure do not usually have epilepsy and do not need antiepileptic drug treatment.
Patients who experience an unprovoked seizure, however, have a significant chance of developing recurrent events (ranging from 31 to 71% depending on other risk factorsloY") and may already have epilepsy. Those with an underlying neurological abnormality or lesion, or who have a recognized syndrome such as juvenile myoclonic epilepsy, are at higher risk and should be treated. There is, in addition, growing evidence that treating a single unprovoked tonic-clonic seizure will prevent others", although it is not likely to alter the overall progno&.
The decision whether or not to treat a patient with an antiepileptic drug should be made after ample discussions of the risks and benefits of both courses of action. The best drug for the patient's seizure type(s) and lifestyle should be selected and administered in a dose that is high enough to bring the circulating concentrations into a relative target (therapeutic) range without producing unacceptable side-effects. Once treatment is instituted, the goal should be restoration of a normal life by complete seizure control using a single medication with no or minimal side-effects. Common errors in treating patients include tolerating occasional seizures in patients who ought to be seizure-free, mistaking cognitive and sedative side-effects of drugs for unavoidable consequences of the epileptic disorder, and failing to refer patients to an epilepsy clinic in a timely fashion.
tion1s-'7. CBZ is regarded as the drug of first choice for partial seizures by most epilepsy specialists. In the USA many neurologists prefer to start with PHT. Some clinicians, particularly in Europe, choose to use VPA ahead of PHT because of the latter's propensity to saturation kinetics and their perception of a less favourable side-effect profile. PB is a second-line drug in most cases, despite its being the least expensive and most widely available, because of its tendency to produce sedation and depression in adults and hyperactivity and aggression in children. Among the newer antiepileptic agents, lamotrigine, gabapentin, vigabatrin, oxcarbazepine, felbamate, topiramate and tiagabine all possess useful efficacy against partial seizures".
Generalized seizures
For tonic-clonic seizures, VPA, PHT and CBZ are all effective. VPA is regarded as the drug of choice for patients with tonic-clonic seizures and spike-wave discharges on the EEG and for other forms of idiopathic generalized epilepsy, particularly myoclinic jerks and absences. Ethosuximide (ESM) still has a limited place for generalized absences. Here the treatment should be aimed to eliminate all three per second spike-wave discharges from the EEG. For those patients in whom absences coexist with tonic-clonic seizures and/or myoclonic jerks, VPA should be preferred. Clonazepam (CLZ) has efficacy against absences, myoclonic jerks and tonic-clonic seizures. Its value is acutely limited by sedation and by the rapid development of tolerance on chronic administration. Lamotrigine appears to be effective for all types of generalized seizures18.
INDIVIDUAL DRUGS CHOICE OF DRUG

Partial seizures
Carbamazepine (CBZ), phenytoin (PHT), phenobarbital (PB), primidone (PRM) and valproic acid (VPA) are all effective in reducing the frequency of partial seizures13-14. CBZ and PHT are better tolerated than PB, and especially PRM13. There is some evidence that CBZ may be more effective than VPA for this indicationr4, but other studies have not supported this asserSubstantial data have accumulated over many decades on the clinical pharmacokinetics of the established antiepileptic drugs (Table 1) . Their indications and a guide to dosing in children and adults are outlined in Tables 2 and 3 . These drugs are not without their hazards and their optimum use must be governed by an appreciation of their potential for dose-related and idiosyncratic toxicity (Table 4) . The clinical use of each drug will be considered, highlighting the practical problems absence or myoclonic seizures2'. It acts by preventing repetitive firing of sodium-dependent action potentials in depolarized neurones21 via use-and voltage-dependent blockade of Na+ channels22. CBZ should be introduced at low dosage (100-200 mg daily) to allow tolerance to develop to its central nervous system sideeffect?. The dose can then increased in 2-4 weekly increments to a maintenance amount that controls the seizure disorder. A balance must be achieved between speed of seizure control and acceptance of temporary central nervous system toxicity. The final dose often depends on the extent of autoinduction of metabolism24.
Carbamazepine
CBZ was synthesized by Schindler at Geigy in 1953 in an attempt to compete with the newly introduced antipsychotic chlorpromazine. The first clinical studies in epilepsy were not carried out until 1963. Over the years CBZ has slowly gained acceptance as an important treatment for partial and tonic-clonic seizures". In Europe, it is usually preferred over PHT. CBZ is not effective, and may even be deleterious, for patients with A contribution to these side-effects is likely to come from the active metabolite CBZ 10,ll epoxide25. These symptoms provide a ceiling to dosage for many patients with refractory epilepsy. In addition, high peak plasma concentrations often result in intermittent side-effects around 2 hours after dosing, necessitating three or four times daily administration in some patients. Such problems can be overcome by prescribing a controlledrelease formulation, now available widely, which can be given once26 or twice*' daily in all patients.
CBZ can cause a range of idiosyncratic reactions, the most common of which is a morbilliform rash in around 10% of patients". Slow dosage titration may reduce this figure*'. Other unusual, but more severe, skin eruptions include erythema multiforme and StevensJohnson syndrome. Reversible, mild leukopenia often occurs, but does not require discontinuation of therapy unless accompanied by evidence of infection or if the white cell count slips below 1 X 109/1. Blood dyscrasias and toxic hepatitis are rarer problems. Long-term side-effects with CBZ are few. At high concentrations, the drug has an antidiuretic, hormone-like action, that can result in fluid retention with cardiac failure in the elderly. Mild hyponatremia is usually asymptomatic, but if the serum sodium falls below 120mmol/l the patient may present with confusion, peripheral oedema and worsening seizure contr0119. Orofacial dyskinesias and cardiac arrhythmias are other occasional complications.
As well as inducing its own metabolism, CBZ can accelerate the breakdown of a number of other lipid-soluble drugs29. The commonest interaction is with the oral contraceptive pill, necessitating for most women a daily oestrogen dose of 50 mcg or more30. Other important metabolic targets include VPA, ESM, corticosteroids, anticoagulants, antipsychotics and cyclosporin. Drugs that inhibit CBZ metabolism resulting in toxicity include PHT, cimetidine, dextropropoxyphene, diltiazem, erythromycin, isoniazid, verapamil and viloxaxine. An important pharmacodynamic interaction takes place with lamotrigine, resulting in headache, nausea, dizziness, diplopia and ataxia which responds to a reduction in the dose of either drug3'. The less common neurotoxic interaction with lithium (confusion, disorientation, drowsiness, ataxia, termor, hyperreflexia) is also not associated with altered drug concentrations3*.
The substantial variation in any given individual in CBZ concentrations over the course of the day-as much as 100% with twice-daily dosing-makes the interpretation of concentration monitoring problematical.
In many patients, the dosage can be titrated adequately on clinical criteria alone33. Exceptions include those in whom compliance is suspect and patients taking a cocktail of antiepileptic drugs like to interact mutually. The appreciation that an epileptic seizure was accompanied by an electrical 'storm' in the brain led Houston Merritt and Tracy Putnam to screen a wide of variety of phenyl compounds against electrically induced seizures in cats in the belief that this chemical grouping was responsible for the anticonvulsant effect of PB. This led rapidly to the discovery of PHT. Several mechanisms have been implicated in explaining its antiepileptic action, but voltage-and use-dependent blockade of Na' channels appears to be the primary one 34 It can also reduce the amplitude of . synaptic potentials, but at low stimulus frequencies this effect is relatively smal13'. PHT is an effective treatment for partial and tonic-clonic seizures. It is one of a handful of drugs that switches from first-order to saturation kinetics at therapeutic dosage36. Accordingly, at concentrations around 60~mol/l (15 mg/l) a moderate increment in dose can produce an unexpectedly large rise in plasma level with accompanying neurotoxicity.
Conversely, the circulating concentration can fall precipitously when the dose is reduced mostly, sometimes resulting in seizure breakthrough. The dosage, therefore, producing the same circulating concentration, varies greatly among individuals.
A starting amount of 5 mg/kg body weight will produce concentrations within the target range of 40-80 pmol/I (lo-20 mg/I) in most patients. Some, however, will saturate at this dose and present with neurotoxicity. Others will require a much higher dose, particularly enzyme-induced alcohol abusers. Below 32 pmol/l (8 mg/l), an increment not exceeding 100 mg can be made; patients with PHT concentrations above 32 pmol/l (8 pg/ml) should receive smaller dosage increments (no more than 50mg) with frequent monitoring. At levels nearing the upper limit of the target range, the dose should be increased by as little as 25 mg daily. Some patients will tolerate concentrations above 100 pmol/l (25 mg/l) with benefit.
PHT can produce a range of dose-related and idiosyncratic adverse effects (Table 4) . Of the latter, cosmetic changes (gum hyperplasmia, acne, hirsutism, facial coarsening), although often mild, can be troublesome. Symptoms of neurotoxicity (drowsiness, dysarthria, tremor, ataxia, cognitive difficulties) become increasingly likely the more the concentration exceeds 80pmol/l (20mg/l). Younger patients may report nausea and vomiting. The diagnosis of PHT toxicity should be made on clinical grounds and not be assumed from a high concentration. The patient will complain of mental slowing and unsteadiness, and neurological examination will reveal nystagmus and ataxia. Heel-toe walking is particularly sensitive. Permanent cerebellar damage3' may be a consequence of chronic toxicity, and so it is important to examine the patient regularly. A paradoxical increase in seizure frequency may also point the way to PHT toxicity.
PHT The anticonvulsant properties of VPA were recognized serendipitously in 1963, when it was used by Pierre Eymard as a solvent for a number of other compounds. It is now established as effective over the complete range of seizure types, with particular value in the idiopathic generalized epilepsies4'. VPA's mechanism of action is poorly understood4'. It is currently believed to exert its antiepileptic effects, at least in part, by a mechanism similar to that of PHT and CBZ, limiting sustained repetitive firing by use-and voltage-dependent effect on Na+ channels4'. However, VPA has many active metabolities whose effects are not well characterized and, given its wide spectrum of antiepileptic activity, other cellular mechanisms are likely to be involved.
The starting dose for adults and adolescents should be 500mg daily for 1 or 2 weeks, increasing in most patients to 500 mg twice daily. Alterations thereafter can be made according to the clinical status of the patient. Many patients will need to take 1500-2000 mg daily. Since the drug can take several weeks to become fully effective, frequent dosage adjustments shortly after initiating therapy are unwarranted. Because VPA does not exhibit a clear-cut concentration effect-toxicity relationship and daily variations in concentration at a given dose are wide, routine monitoring may not be helpful unless correlated with the patient's clinica situation. In addition, patients frequently need and tolerate concentrations up to 1040 pmolll (150 mg/l).
Common unpleasant side-effects with VPA are dose-related tremor, weight gain, thinning or loss of hair (usually temporary), and menstrual irregularities including amenorrhea.
There is some evidence implicating its use in the production of polycystic ovariesJ3. Sedation is an uncommon complaint although stupor and encephalopathy can occur, possibly as a consequence of underlying carnitine deficiency". Hepatoxicity, histologically a microvesicular steatosis similar to that found in Reye's syndrome, affects fewer than one in 20,000 treated individuals. This appears to be a particular worry in children under 3 years-of-age receiving antiepileptic polypharmacy, some of whom will have a co-existent metabolic defect45. Hyperammonemia without hepatic damage can be demonstrated in approximately 20% of all patients receiving VPA46. This is usually transient, but occasionally can present clinically with confusion, nausea and vomiting, and clouding of consciousness. Other sporadic problems include thrombocytopenia and pancreatitis.
VPA can inhibit a range of hepatic metabolic processes, including oxidation, conjugation and epoxidation4'. Targets include other antiepileptic drugs, particularly PHT, PB, CBZ epoxide and lamotrigine31.
Aspirin displaces VPA from its binding sites on plasma proteins and inhibits its metabolism4'.
VPA does not interfere with the hormonal components of the oral contraceptive pill.
Phenobarbital
The discovery of the antiepileptic properties of PB was another classic example of serendipity. A German physician, Alfred Hauptmann, had been assigned rooms over his ward of patients with epilepsy. Unable to get a night of uninterrupted sleep, he provided them with a blanket prescription of PB as an hypnotic. To his surprise and delight, this treatment reduced the number of seizures during the night and throughout the day. PB is used worldwide and recent trials have confirmed it to be as effective as CBZ and PHT in abolishing partial and generalized tonic-clonic seizures13. The anticonvulsant effects of PB are believed to be mediated through potentiation of gamma aminobutyric acid (GABA) inhibition by binding to a specific site on the GABA* receptor chloride channel complex. At a cellular level, PB produces a prolongation of inhibitory postsynaptic potentials by increasing the mean chloride channel opening time and the duration of GABA-induced bursts4'.
PB is an easy drug to use clinically. To minimize sedation, a low dose should be started (60 mg in adults, 4 mg/kg in children), which can be increased gradually according to clinical requirements. The value of measuring circulating PB is limited as the concentration associated with optimal control varies considerablJ'.
In addition, the development of tolerance to its central nervous side-effects makes the toxic threshold imprecise. Nevertheless, an unexpectedly low or high concentration may help to make the correct clinical decision in an individual patient.
The major problem in the clinical use of PB lies in its propensity to influence cognition, mood and behaviour. It can produce fatigue, listlessness and tiredness in adults and insomnia, hyperactivity and aggression in children (and sometimes in the elderly)". Subtle impairment-of memory, mood and learning capacity can occur in both groups. Depression may be associated with long-term administration, and arthritic changes and Dupuytren's contracture can be associated problems. Tolerance develops to the deleterious cognitive effects but also, unfortunately, to its anticonvulsant efficacy in some patient$l. PB is the archetypal enzyme inducer and can accelerate the metabolism of a long list of lipid-soluble drugs5*.
Primidone PRM was synthesized initially in an attempt to produce a non-sedative barbiturate.
The first clinical trials in epilepsy took place in 1952. It was not appreciated for some time that the parent drug was biotransformed to PB and another active metabolite, phenylethylmalonamide. The efficacy of PRM is similar to that of PB, but it is less well tolerated13. Not surprisingly, withdrawal may result in seizure exacerbation. There is, therefore, little to recommend this drug over PB for those patients in whom treatment with a barbiturate is contemplated.
A poor correlation exists between PRM concentrations and efficacy and toxicit$'. The major metabolite, PB, can be measured if compliance is an issue. ESM acts by reducing low threshold, transient, voltage-dependent calcium conductance in thalamic neurons53. Slow introduction is sensible to anticipate the development of gastrointestinal and central nervous system side-effects. In children over 6 years, 500 mg/day is a reasonable starting dose, with further increments as necessary to a maximum amount of l-2g daily. For most patients the dose can be increased every 2-4 weeks. Infants require higher weight-related dosing, i.e. 15-30 mg/kg daily.
The side-effects of ESM are dose-related and usually involve the gastrointestinal tract (nausea,
with telemetry. Routine drug monitoring is not necessary, but a measurement can be helpful in distinguishing a patient who is resistant to ESM's pharmacological effect from one who has low concentrations as a consequence of incomplete compliance or rapid degradation33. ESM itself does not interfere with drug metabolism, but does provide a target for enzyme inducers such as PI-IT and CBZ, or inhibitors such as VPA38.
Clobazam
Clobazam (CLB) was introduced as an anxiolytic in 1975, and its anti-seizure activity was recognized soon after. It is a 1,5 benzodiazepine that exerts its activity by potentiating the inhibitory action of gamma aminobutyric acid54. CLB is a useful adjunctive drug in refractory epilepsy". Only a minority of patients, however, achieve a worthwhile improvement in seizure control on long-term dosing due to the development of tolerance. Some of these will have an anatomical basis for their seizure disorde15. Nevertheless, a useful proportion (lo-20%) will become seizurefree". There is some evidence that intermittent use of CLB reduces the likelihood of tolerance56. Short-term administration, e.g. 20-30 mg daily for 3 days, can be effective in women with catamenial exacerbations and as 'cover' for special events such as holidays, weddings and surgery. A single dose of 30mg can have a prophylactic effect if taken immediately after the fnst seizure in patients who suffer regular clusters of complex partial or secondary generalized seizures. CLB's structure differs slightly from those of clonazepam and diazepam, and this may account for a lesser propensity to produce sedation. Nevertheless, depression, irritability and tiredness are commonly reported5'. As with barbiturates, deterioration in behaviour and mood .disturbance can occur, particularly in patients with learning disabilities in whom CLB should probably be avoided. Withdrawal seizures can also be a problem.
Clonazepam
CZP has efficacy against absences, myoclonic jerks and tonic-clonic seizures58. As with other benzodiazepines, sedation and tolerance substantially reduce its usefulness. Few patients respond well to this drug, and nearly 50% will have an exacerbation of their epilepsy when it is withdrawn5'. Accordingly, it now has a narrow role in the modem management of epilepsy, possibly limited to refractory myoclonic seizures. Like other benzodiazepines, CZP should only be prescribed as a last resort for patients with learning difficulties.
lNDlVlDUALlZATlON OF THERAPY
The choice of drug for the individual patient depends on the seizure type or types and the likely tolerability to potential side-effects. Another important factor is the prescribing clinician's experience. For most patients with partial and tonic-clonic seizures, CBZ is a good first choice. Some individuals have early problems with rash or central nervous system toxicity. If, because of intermittent side-effects, the drug needs to be administered more than twice daily, compliance can become an issue. In such circumstances a controlled-release formulation should be substituted. CBZ induces the metabolism of the hormonal components of the oral contraceptive, and this may cause difficulty in ensuring adequate protection against unwanted pregnancy. Its enzyme-inducing properties can be a major drawback in patients receiving other lipid-soluble drugs such as warfarin, cyclosporin, etc. The association of CBZ with neural tube defects should also be kept in mind when prescribing the drug in female patients of child-bearing potentialm.
PHT is as effective as CBZ against partial and tonic-clonic seizures. It can be administered once or twice daily and a useful parenteral preparation is available. Gum hypertrophy, hirsutism and changes in facial features are unpredictable side-effects. Advice on mouth hygiene can prevent the first of those, and the latter two are often mild and can be reversible. Teratogenesis is a potential problem in this patient population, as is PHT's induction effect on the oral contraceptive pill and other lipid soluble drugs. Saturation kinetics make PI-IT a poor choice for patients whose compliance is likely to be erratic. It is usually necessary to monitor its circulating concentration.
VPA is particularly effective for the idiopathic generalized epilepsies, although it also has efficacy against localization-related tonic-clonic and partial seizures. Its tendency to cause weight gain and patchy hair loss can cause problems, although many patients tolerate the drug well. Teratogenesis, particularly neural tube defects, is undoubtedly a worq@ as is its reported effect in producing polycystic ovaries43. These can be a particular concern to young women with idiopathic generalized seizures, in whom there is . an expanding place for lamotrigine31. Care should be taken when prescribing VPA for infants and young children with suspected inborn errors of metabolism because of the particular risk of hepatotoxicity.
PB, which is as effective as CBZ and PI-IT against partial seizures, is usually reserved for patients intolerant to these agents, as it is sedative and can produce depression. PB is an unattractive alternative for children, because of its deleterious influence on learning and behaviour. In addition, it is the archetypal enzyme inducer and accelerates the metabolism of a range of other lipidsoluble drugs. On the positive side, PB is inexpensive and easy to use. Accordingly, it still has an important role to play in the management of epilepsy in the third world, where cost is the overwhelming consideration in the choice of therapy.
POLYPHARMACY
More than 25% of people with epilepsy appear refractory to optimal therapy with a single antiepileptic drug. Many of these will have partial seizures secondary to an underlying anatomical abnormality. The temptation is to add other drugs until acceptable improvement occurs. Current evidence suggests, however, that this strategy will be successful in only around 10% of such patients .
62 It is likely that combining established drugs with similar, multiple and overlapping modes of action is responsible for this disappointing outcome. Recent placebo-controlled studies with newer agents, some of which have specific mechanisms of action, hold out the possibility of more promising combination therapy for refractory partial seizures'*.
Combining antiepileptic drugs results in a number of deleterious adverse interactions largely involving hepatic metabolic processes. No fewer than four of the established drugs, CBZ, PHT, PB and PRM (metabolized in part to PB) have the ability to induce the synthesis of oxidative and conjugating enzymes3g. All will accelerate the breakdown of VPA, ESM and CZP. When given together, mutual enzyme induction is often the result. The exception appears to be with CBZ and PHT. When combined, PHT induces CBZ metabolism, whereas CBZ, paradoxically, reduces the clearance of PHp3. The result is a rise in PHT concentration accompanied by a fall in that of CBZ. Interactions with CBZ can be complicated by an increase in the concentration of the active metabolite, CBZ lo,11 epoxide, which occurs during dual therapy with enzyme-inducing antiepileptic drugs and with the inhibitor VPAU. VPA also inhibits PHT, PB and lamotrigine metabolism65. The extent of the metabolic interactions between antiepileptic drugs varies substantially among patients. With many, there will be no clinical repercussions. Others will suffer a major alteration in circulating concentration resulting in seizure exacerbation or neurotoxicity. Measuring the total drug concentration will often help with appropriate dosage adjustment@. It is important, too, that discontinuing an enzymeinducing or inhibiting drug may have a substantial influence on the concentration of the remaining agent@'.
It has been known for some time that antiepileptic drugs in combination can impair cognition68. This may, in part, be due to the severity of the underlying seizure disorder, particularly in the presence of brain pathology6'. However, the weight of evidence strongly supports an additive effect with established antiepileptic drugs and has contributed to the strong pressure toward monotherapy".
A multifactorial situation involving seizure severity, anatomical disease, and kinetic and dynamic drug interactions offers the most plausible explanation for this phenomenon. Antiepileptic polypharmacy is also more likely to result in teratogenesis and this will be discussed later.
REFRACTORY EPILEPSY
As many as 20% of patients referred to a specialist service with refractory seizures will not have epilepsy at all. Most of these will have pseudoseizures71. Clues to this diagnosis include wide variation in the clinical presentation of the events, aggressive behaviour during the episodes, normal or non-specific electroencephalographic changes, and worsening of seizure control on adding a small dose of an antiepileptic drug. Some of these patients will be young women, who have been sexually abused'*. Other patients do have epilepsy, but will be receiving inappropriate treatment, in particular CBZ or PHT for syndromes involving myoclonic jerks. A few will have absences treated with drugs other than VPA or ESM. Some will have an indolent glioma. Erratic compliance or covert alcoholism or drug abuse are other reasons for apparent 'refractoriness'.
Before treating a patient with more than one antiepileptic drug, all reasonable monotherapy options should be exhausted. This may consist of just one first-line drug tolerated at high dosage in some circumstances, e.g. if there is an underlying resectable lesion. An alternative drug should be introduced slowly. If successful, the original drug can often be withdrawn, although not in all patients .
73 If seizure control remains poor at the highest tolerated dose of a second first-line drug, it is time to try dual therapy. There are no controlled clinical trials to tell us what are the best drugs to combine. For partial and generalized seizures, many specialists employ two of the three first-line agents, namely CBZ, VPA and PHT, although their mechanisms of action are complex and overlapping. A more logical approach may be to add one of the newer antiepileptic drugs with a different mechanism of action. For myoclonic seizures not responding to VPA, lamotrigine or a benzodiazepine such as CZP can be added, while intractable typical or atypical absences may respond to VPA and ESM74 or lamotrigine75 in combination. It would be counter-productive to introduce a sedative drug such as PB or PI&l at this stage, since, if this strategy is ineffective, subsequent withdrawal of the barbiturate will almost certainly produce withdrawal seizures. If the problem is refractory partial seizures, the addition of one of the newer drugs-lamotrigine, vigabatrin, gabapentin, oxcarbazepine, topiramate or tiagabine-may be more appropriate".
There is mounting evidence to suggest that VPA and lamotrigine in combination may be particularly effective for a number of seizure types3',".
In some patients truly refractory to pharmacotherapy, the law of diminishing returns will require patient and doctor to accept the persistence of some seizures. In such a situation, it is important to balance adequacy of control with optimal quality of life. If seizures continue despite treatment with multiple antiepileptic drugs, little can be lost in many patients by gradually reducing the number of drugs and simplifying the dosage schedules. This manoeuvre will often, paradoxically, reduce seizure frequency76. Unfortunately, in a few patients seizure frequency may dramatically worsen or tonic-clonic seizures emerge. Slow reduction will avoid the likelihood of status epilepticus. Producing less intrusive episodes, abolishing tonic-clonic seizures, preventing falls, and decreasing automatisms can all be acceptable end-points in patients with difficult epilepsy. Other important options include early work-up for epilepsy surgery or trying a range of new antiepileptic drugs. This latter alternative is unlikely to be successful if the patient is already taking high doses of three antiepileptic drugs! THERAPEUTIC DRUG MONITORING Although monitoring antiepileptic drug concentrations can be helpful in optimizing the dose in some patients, rigorous adherence to a narrow concentration range is likely to result in the doctor treating the drug level and not the patient".
The 'therapeutic' or, better, 'target' range can only be regarded as an approximation, based as it is on population data. Some patients will do well with levels below the lower limit of the target'*, whereas other require concentrations above the range to become seizure-free79. All too often the dose is reduced because of a reported 'toxic' level, when the patient is symptom-and seizure-free. In other patients who are not fully controlled, the dose may not be increased appropriately for fear of stepping outside a mythical 'therapeutic' range.
Nevertheless, appropriate use of concentration monitoring, particularly on site at an epilepsy clinic, can promote an improved outcomexO. Once treatment is initiated, the goal is complete seizure control using a single drug with no or minimal side-effects. It makes sense, therefore, to ensure that the concentration in a patient with newly diagnosed epilepsy, who may well have infrequent seizures, is within the relevant target range to optimize the likelihood of perfect control. Levels are useful also in encouraging compliance. Monitoring can be helpful in a well-controlled patient with a break through seizure. A lower than expected concentration may indicate a change in metabolism (e.g. CBZ inducing its own metabolism), may reflect an unexpected interaction with another drug, or may suggest a lapse in compliance, a particular problem in adolescents.
Levels can distinguish between too much medication and too little. For example, some patients with partial seizures complain of memory difficulties. This can result from the pathology underlying the seizure disorder, from the seizures themselves, from subclinical ictal discharges, or from a deleterious effect of medication. A concentration measurement can determine whether or not a new symptom is likely to represent a side-effect of treatment. Monitoring can also be useful in circumstances where concentrations vary unexpectedly or unpredictably. For a drug like PHT, which undergoes saturation kinetics, neurotoxic symptoms may occur after a small increment in dose. Concentrations may be altered by co-administered medications (especially enzyme inducers and inhibitors), during pregnancy, in patients with renal or hepatic impairment, or when other medical conditions, e.g. thyroid disorders, co-exist. Although therapeutic drug monitoring can facilitate patient management, its major limitations must also be appreciated".
Drug concentrations vary widely over the course of a day and so monitoring is best related to the time since dosing. Another potential pitfall is the presence of active metabolites (e.g. with VPA or CBZ). Certian drug interactions will lower the parent drug level, while elevating that of a potentially toxic metabolite.
Finally, the therapeutic and unwanted effects of antiepileptic drugs may occasionally be reflected better by free than by total concentrationss2. In most circumstances, these will correlate well. This is not the case, however, when protein-binding is reduced. Such situations occur in the neonate, in old age, in pregnancy, in severe renal and hepatic impairment, and with the co-prescription of drugs that can alter binding. The methodology for measuring free levels is more complex, less reliable, and more expensive than assaying total drug concentrations. However, when a patient experiences an unexpected degree of toxicity at apparently modest or moderate dosage, measurement of the free level may indicate the cause.
PREGNANCY
Most women with treated epilepsy undergo uneventful pregnancies and deliver healthy babiess3. During pregnancy, however, metabolic and excitatory processes change and closer attention should be given to antiepileptic drug concentrations. Total levels of some established drugs will fall, particularly those of PHP. Women who are well controlled will usually remain so during pregnancy and delivery. However, those who continue to report seizures may suffer a deterioration. There is a small increased incidence of significant fetal malformations in the offspring of epileptic women, even if they are untreated&. Commonly quoted figures are 2% in the general population compared with 3% for women with epilepsy. The risk increases with the number of antiepileptic drugs, being approximately 3% for one drug (similar to background), 5% for two, 10% for three, and over 20% in women taking as many as four antiepileptic drugs .
86 The mechanism is likely to involve the production of mutagenic metabolitess7.
A syndrome consisting of facial dimorphism, cleft lip and palate, cardiac defects, digital hypoplasia and nail dysplasia has been identified. This was initially ascribed to hydantoins including PHT ('fetal-hydantoin syndrome'), but is now known to occur with most other antiepileptic drugs, including CBZ and VPAs7. There are no clear data indicating differences in safety among PHT, PB or PRM. Current evidence suggests, however, that VPA and CBZ are associated with a low incidence of neural tube defects, probably l-2% and OS-l%, respectively88.
Although it would be ideal for a woman contemplating pregnancy to have her antiepileptic medication withdrawn, for many this would result in recurrence or exacerbation of seizures, which could be dangerous for both mother and baby. If the criteria for discontinuation of medication are met, this should be done over a suitable interval before conception. Other patients should be tapered to a minimal effective dose of, if possible, a single antiepileptic drug. In addition, supplemental folic acid should be administered preconceptually in an attempt at preventing neural tube defects. To be effective, folate must be taken during the first 5 weeks of gestation. The current recommendations are 5 mg/day folic acid for women who have had a child with such a defect, and 0.4 mg daily in other women planning a pregnancy". It seems sensible, however, to recommend the full 5 mg folate daily for all women receiving treatment with antiepileptic drugs=.
Eznyme-inducing antiepileptic drugs (CBZ, PHT, PB and PRM) can cause transient and reversible deficiency in vitamin K-dependent clotting factors in the neonate. Following a traumatic birth, there is an increased risk of intracerebral hemorrhage. Accordingly, pregnant women receiving one or more of these drugs should be treated with 20 mg of vitamin K1 daily during the last month of pregnancy, and babies at risk should receive a single intramuscular dose of 1 mg of vitamin K, immediately after birthgO.
WITHDRAWING TREATMENT
A successful outcome for treated epilepsy can be regarded as a patient who becomes seizure-free in the absence of, adverse effects. Such individuals usually lead integrated lives, with successful intellectual and emotional development and positive educational and vocational achievements. Indeed, many such patients can eventually have their medication withdrawn and will remain seizure-free". Patients who are 'doing well' may want to stop treatment for a variety of reasons, including the presence of unpleasant side-effects or the subjective perception of subtle deterioration in cognitive function. In addition, taking medication does not equate with normal health. If drug therapy is stopped and seizures do not recur, there is a sense of being 'cured' of the stigma of epilepsy. Finally, patients may want to become parents and are often concerned about the possible negative effects of antiepileptic drugs on reproductive function and about the spectre of teratogenesis. Several studies have shown that after a period of optimal seizure control, medication can be stopped without recurrence (at least within several years) in more than 60% of patients92-96.
There are no data to indicate an optimum length for the seizure-free period; most studies used 2-5 years9'. Seizure type or epilepsy syndrome is not absolutely predictive of recurrence. However, a few specific childhood syndromes, such as benign epilepsy of childhood with rolandic spikes and benign familial neonatal convulsions, tend to do well after drug withdrawal, whereas juvenile myoclonic epilepsy conveys a high probability of relapse. Some forms of idiopathic generalized seizures, either absence or tonic-clonic, if existing alone, are less likely to recur after control is achieved. However, even complex partial seizures can disappear after a long period of perfect control. Individuals with the highest probability of remaining seizure-free after medication is discontinued are those reporting no seizures for a long period, those with relatively few seizures before control was achieved, those taking a single antiepileptic drug, and those with a normal neurological examination with no structural brain lesion98. The role of the EEG in predicting seizure recurrence is somewhat more controversialWV9*. Some studies have indicated a low predictive value for this investigation, whereas others have suggested a better prognosis for continued remission when the EEG is normal. There are no protocols defining optimal regimens for tapering medication. Most specialists advise slow reduction over periods ranging from 2 to 6 months. If the patient is taking antiepileptic polypharmacy, one drug should be completely withdrawn before the second is tapered. More than 90% of recurrences will occur during the 1st year following withdrawal, and most will present during the taper period or shortly after.
EPILEPSY PROPHYLAXIS
Some individuals are known to be at high risk of developing epilepsy. These include those with severe head trauma, significant central nervous system infection, supratentorial brain tumour, ventricular shunt, arteriovenous malformation, haemorrhagic stroke, etc. There are few data exploring the efficacy of antiepileptic drugs in preventing its development. One controlled trial showed that PHT could suppress seizures acutely after head injury99, but another did notIm. There is doubt, too, regarding their efficacy in preventing the development of chronic epilepsy10'*'02. Other trials have suggested that high serum antiepileptic drug concentrations are needed for successful prophylaxis'03. At the present time, it is difficult to recommend prophylactic antiepileptic treatment, but more research is needed in this important area.
REFERRAL TO AN EPILEPSY CENTRE
Some individuals with uncomplicated epilepsy are cared for by family practitioners, general physicians or pediatricians. However, as proper diagnosis, accurate seizure and epilepsy syndrome classification, and appropriate selection and supervision of medication is essential for optimal management, is is often in the patient's best interests to involve a neurologist or other epilepsy specialist early in the evaluation. Patients with complicated seizure problems are more appropriately cared for by an epileptologist, who can provide additional expertise in diagnosis and treatment.
If patients continue to have seizures, not clearly due to erratic compliance with medication, referral to an epilepsy centre can be essential for a number of reasons. Firstly, it appears that the more seizures an individual experiences, the more difficult they are to control. That 'seizures (may) beget seizures' has been hypothesized for more than 100 years'03. Thus, tolerating prolonged periods of uncontrolled seizures may be prognostically deleterious. Secondly, seizure classification may be hard to determine based on untrained witness accounts. Video-EEG monitoring can provide a definitive diagnosis and classification, which can lead to more effective therapy. Some patients with 'uncontrolled seizures' are really having pseudoseizures, which are better treated by psychotherapy and, often, reduction in or withdrawal of antiepileptic medication. Thirdly, patients with uncontrolled seizures often receive polypharmacy and this may produce significant toxicity, which can be reduced by careful pharmacological simplification under monitored conditions'"4. Fourthly, patients who have failed to respond adequately to the standard drugs will have the opportunity to try one or more newer agents under carefully controlled conditions at an epilepsy centre. Lastly, appropriate decisions about surgery can best be made in a specialized centre.
CONCLUSIONS
In this paper, we have attempted an overview of the practical management of epilepsy using established antiepileptic drugs. When prescribing these agents, the following 12 basic rules should be followed:
1.
2.
3.
4.
5.
6.
7.
Ensure that the diagnosis of epilepsy is soundly based, that there is no other underlying correctable condition, and that the patient understands and accepts the necessity of taking antiepileptic drug therapy for some years; Choose the best drug for each individual patient using the international classifications of seizure types and epilepsy syndromes; Start at low dosage and titrate upwards in increments to a maintenance amount that controls the seizures but permits tolerance to central nervous system side-effects and avoids concentration-dependent toxicity; Keep the regimen simple with once or twice-daily dosing when possible; Counsel the patient early regarding the implications of the diagnosis, the prophylactic nature of the therapy, and the importance of perfect compliance; In patients proving resistant to a first-line drug but not complaining of side-effects, titrate the dose to the limit of tolerability without worrying about the circulating concentration: As monotherapy is the preferred approach for the majority of patients, a second drug should usually be substituted before embarking upon dual therapy; 
